U.S., Aug. 22 -- ClinicalTrials.gov registry received information related to the study (NCT07135102) titled 'A Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of [225Ac]Ac-PSMA-XT Injection in Patients With Metastatic Castration-resistant Prostate Cancer' on Aug. 14.
Brief Summary: The purpose of this study is to determine the safety and efficacy of 225Ac -labeled PSMA ligand(PSMA-XT) in the treatment of mCRPC
Study Start Date: Oct. 14, 2024
Study Type: INTERVENTIONAL
Condition:
Metastatic Castration-Resistant Prostate Cancer Patients
Intervention:
DRUG: 225Ac-PSMA-XT
Patients will receive 225Ac-PSMA-XT administration at an interval of 6 weeks between each dose.
Recruitment Status: RECRUITING
Sponsor: ...